Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery
Head and Neck Squamous Cell Carcinoma
Other: Laboratory Biomarker Analysis
Biological: Recombinant Interleukin-12
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Phase I/II Trial of Cetuximab in Combination With Interleukin-12 Administered to Patients With Unresectable Primary or Recurrent Squamous Cell Carcinoma of the Head and Neck|
- Number of dose-limiting toxicity incidents to determine the maximum tolerated dose of IL-12, evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (phase I) [ Time Frame: 14 days ] [ Designated as safety issue: Yes ]
- Proportion of patients who have any response to treatment (complete response or partial response), determined according to Response Evaluation Criteria in Solid Tumors (phase II) [ Time Frame: Up to 6 months ] [ Designated as safety issue: No ]The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. Ninety percent confidence intervals for the true success proportion will be calculated according to the approach of Duffy and Santner.
- Induction of systemic plasma levels of interferon-gamma [ Time Frame: Baseline up to day 50 ] [ Designated as safety issue: No ]Explores graphically how changes in this marker differ between those with versus without an objective response to therapy as well as other potential factors.
- Number of confirmed clinical responses (phase I) [ Time Frame: Up to 6 months ] [ Designated as safety issue: No ]Summarized by simple descriptive summary statistics.
- Overall survival (phase II) [ Time Frame: From the date of registration to date of death, assessed up to 1 year ] [ Designated as safety issue: No ]The Kaplan-Meier method will be used to estimate overall survival distribution.
- Proportion of patients who are progression-free (phase I) [ Time Frame: 6 months ] [ Designated as safety issue: No ]Summarized by simple descriptive summary statistics.
- Time to disease progression (phase II) [ Time Frame: From date of registration to date of progression, assessed up to 1 year ] [ Designated as safety issue: No ]The Kaplan-Meier method will be used to estimate time to progression distributions.
|Study Start Date:||October 2011|
|Estimated Primary Completion Date:||December 2015 (Final data collection date for primary outcome measure)|
Experimental: Treatment (cetuximab and recombinant interleukin-12)
Patients receive cetuximab IV over 1-2 hours on day 1 and recombinant interleukin-12 SC on days 2 and 5 beginning in course 2. Treatment repeats every 2 weeks for 12 courses in the absence of disease progression or unacceptable toxicity. Patients achieving clinical response or stable disease may continue with therapy until disease progression.
Other Names:Other: Laboratory Biomarker Analysis
Correlative studiesBiological: Recombinant Interleukin-12
I. To find a safe and tolerable interleukin (IL)-12 (recombinant interleukin-12) dose for use in combination with cetuximab in patients with squamous cell carcinoma of the head and neck. (Phase I) II. To determine the response rate to the combination of IL-12 and cetuximab. (Phase II)
I. To characterize the immunologic effects of IL-12 when administered in combination with cetuximab.
OUTLINE: This is a phase I, dose-escalation study of recombinant IL-12 followed by a phase II study.
Patients receive cetuximab intravenously (IV) over 1-2 hours on day 1 and recombinant interleukin-12 subcutaneously (SC) on days 2 and 5 beginning in course 2. Treatment repeats every 2 weeks for 12 courses in the absence of disease progression or unacceptable toxicity. Patients achieving clinical response or stable disease may continue with therapy until disease progression.
After completion of study treatment, patients are followed up for 1 year.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01468896
|United States, District of Columbia|
|MedStar Georgetown University Hospital||Recruiting|
|Washington, District of Columbia, United States, 20007|
|Contact: Stephen V. Liu 202-444-7935 email@example.com|
|Principal Investigator: Stephen V. Liu|
|United States, New York|
|Roswell Park Cancer Institute||Recruiting|
|Buffalo, New York, United States, 14263|
|Contact: Yujie Zhao 716-845-8568 firstname.lastname@example.org|
|Principal Investigator: Yujie Zhao|
|United States, Ohio|
|Ohio State University Comprehensive Cancer Center||Recruiting|
|Columbus, Ohio, United States, 43210|
|Contact: William E. Carson 614-293-6306 email@example.com|
|Principal Investigator: William E. Carson|
|Principal Investigator:||William Carson||Ohio State University Comprehensive Cancer Center|